Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 2
2005 1
2006 1
2007 4
2008 3
2009 3
2010 3
2011 5
2012 1
2013 1
2014 1
2015 1
2016 3
2019 2
2020 3
2021 1
2022 3
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Long-term follow-up of congenital hydronephrosis in a single-center study.
Morizawa Y, Aoki K, Fukui S, Tomizawa M, Shimizu T, Onishi K, Hori S, Gotoh D, Nakai Y, Miyake M, Torimoto K, Fujimoto K, Otani T, Fujimoto K. Morizawa Y, et al. Among authors: otani t. Int J Urol. 2024 Jan 11. doi: 10.1111/iju.15391. Online ahead of print. Int J Urol. 2024. PMID: 38205874
Tumor-specific delivery of biologics by a novel T-cell line HOZOT.
Onishi T, Tazawa H, Hashimoto Y, Takeuchi M, Otani T, Nakamura S, Sakurai F, Mizuguchi H, Kishimoto H, Umeda Y, Shirakawa Y, Urata Y, Kagawa S, Fujiwara T. Onishi T, et al. Among authors: otani t. Sci Rep. 2016 Nov 30;6:38060. doi: 10.1038/srep38060. Sci Rep. 2016. PMID: 27901098 Free PMC article.
First-line pembrolizumab for patients with early relapsing urothelial carcinoma after perioperative chemotherapy: a retrospective analysis of bladder cancer and upper urinary tract cancer.
Nishimura N, Miyake M, Shimizu T, Matsubara T, Miyamoto T, Sakamoto K, Yamada A, Matsumoto Y, Yoshikawa M, Ichikawa K, Omori C, Maesaka F, Oda Y, Kiba K, Tomioka A, Hosokawa Y, Tanaka M, Otani T, Fujimoto K. Nishimura N, et al. Among authors: otani t. Int J Clin Oncol. 2022 Nov;27(11):1733-1741. doi: 10.1007/s10147-022-02230-9. Epub 2022 Aug 27. Int J Clin Oncol. 2022. PMID: 36029377
External validation of a genitourinary cancer-specific prognostic scoring system to predict survival for patients with bone metastasis (modified B-FOM scoring model): Comparison with other scoring models in terms of accuracy.
Owari T, Miyake M, Nakai Y, Tanaka N, Itami Y, Hirao S, Momose H, Nakagawa Y, Iida K, Maesaka F, Shimizu T, Iemura Y, Matsumoto Y, Kuwada M, Otani T, Otsuka K, Okajima E, Hosokawa Y, Okamura R, Fujimoto K. Owari T, et al. Among authors: otani t. J Bone Oncol. 2020 Dec 13;26:100344. doi: 10.1016/j.jbo.2020.100344. eCollection 2021 Feb. J Bone Oncol. 2020. PMID: 33384916 Free PMC article.
Clinical benefit of early treatment with bone-modifying agents for preventing skeletal-related events in patients with genitourinary cancer with bone metastasis: A multi-institutional retrospective study.
Owari T, Miyake M, Nakai Y, Hori S, Tomizawa M, Ichikawa K, Shimizu T, Iida K, Samma S, Iemura Y, Momose H, Omori C, Otani T, Kuwada M, Hirao S, Oyama N, Nakagawa Y, Hayashi Y, Tanaka N, Fujimoto K. Owari T, et al. Among authors: otani t. Int J Urol. 2019 Jun;26(6):630-637. doi: 10.1111/iju.13939. Epub 2019 Mar 18. Int J Urol. 2019. PMID: 30883931
39 results